Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media

Vaccine

Volumn 24, Issue 27-28, 2006, Pages 5584-5592

  Sabirov, Albert ^a   Metzger, Dennis W ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Neonatal vaccination; Otitis media; Pneumococcus

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INOCULATION; MOUSE; MOUSE STRAIN; NEWBORN; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; VACCINATION; WILD TYPE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; EAR, MIDDLE; IMMUNITY, MUCOSAL; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 33744974789     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.033     Document Type: Article

References (43)

1. Faden H. The microbiologic and immunologic basis for recurrent otitis media in children. Eur J Pediatr 160 (2001) 407-413
2. Arriaga M.A., Bluestone C.D., and Stool S.E. The role of tympanocentesis in the management of infants with sepsis. Laryngoscope 99 (1989) 1048-1051
3. Burton D.M., Seid A.B., Kearns D.B., and Pransky S.M. Neonatal otitis media. An update. Arch Otolaryngol Head Neck Surg 119 (1993) 672-675
4. Raz R., Elhanan G., Shimoni Z., Kitzes R., Rudnicki C., Igra Y., and Yinnon A. Pneumococcal bacteremia in hospitalized Israeli adults: epidemiology and resistance to penicillin. Israeli Adult Pneumococcal Bacteremia Group. Clin Infect Dis 24 (1997) 1164-1168
5. Schutzman S.A., Petrycki S., and Fleisher G.R. Bacteremia with otitis media. Pediatrics 87 (1991) 48-53
6. Pelton S.I. Vaccination for the prevention of acute otitis media: proof of concept and current challenges. Pediatr Ann 31 (2002) 804-809
7. Harrison C.J. Changes in treatment strategies for acute otitis media after full implementation of the pneumococcal seven valent conjugate vaccine. Pediatr Infect Dis J 22 (2003) 120-130
8. Shinefield H.R., and Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J 19 (2000) 394-397
9. Jakobsen H., and Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria-new potentials for conjugate vaccines?. Scand J Immunol 58 (2003) 119-128
10. Kauppi-Korkeila M., Saarinen L., Eskola J., and Käyhty H. Subclass distribution of IgA antibodies in saliva and serum after immunization with Haemophilus influenzae type b conjugate vaccines. Clin Exp Immunol 111 (1998) 237-242
11. Nurkka A., Ahman H., Yaich M., Eskola J., and Kayhty H. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines PncD and PncT. Vaccine 20 (2001) 194-201
12. Jakobsen H., Saeland E., Gizurarson S., Schulz D., and Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Inf Imm 67 (1999) 4128-4133
13. Lynch J.M., Briles D.E., and Metzger D.W. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 71 (2003) 4780-4788
14. Sun K., Johansen F.E., Eckmann L., and Metzger D.W. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J Immunol 173 (2004) 4576-4581
15. Kodama S., Suenaga S., Hirano T., Suzuki M., and Mogi G. Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Inf Imm 68 (2000) 2294-2300
16. Suenaga S., Satoru K., Ueyama S., Suzuki M., and Mogi G. Mucosal immunity of the middle ear: analysis at the single cell level. Laryngoscope 111 (2001) 290-296
17. Long J.P., Tong H.H., and DeMaria T.F. Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media model. Inf Imm 72 (2004) 4309-4313
18. Malley R., Morse S.C., Leite L.C., Areas A.P., Ho P.L., Kubrusly F.S., Almeida I.C., and Anderson P. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Inf Imm 72 (2004) 4290-4292
19. van der Ven L.T.M., Van den Dobbelsteen G.P., Nagarajah B., van Dijken H., Dortand P.M., Vos J.G., et al. A new rat model of otitis media caused by Streptococcus pneumoniae: conditions and application in immunization protocols. Inf Imm 67 (1999) 6098-6103
20. Sabirov A., Kodama S., Hirano T., Suzuki M., and Mogi G. Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Inf Imm 69 (2001) 2964-2971
21. Buchanan J.M., Vogel L.A., Van C.V., and Metzger D.W. Interleukin 12 alters the isotype-restricted antibody response of mice to hen eggwhite lysozyme. Int Immunol 7 (1995) 1519-1528
22. Buchanan R.M., Briles D.E., Arulanandam B.P., Westerink M.A., Raeder R.H., and Metzger D.W. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine 19 (2001) 2020-2028
23. Melhus A., and Ryan A.F. A mouse model for acute otitis media. APMIS 111 (2003) 989-994
24. Jakobsen H., Bjarnarson S., Del Giudice G., Moreau M., Siegrist C.A., and Jonsdottir I. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun 70 (2002) 1443-1452
25. Kovarik J., and Siegrist C.A. Immunity in early life. Immunol Today 19 (1998) 150-152
26. Posfay-Barbe K.M., and Wald E.R. Pneumococcal vaccines: do they prevent infection and how?. Curr Opin Infect Dis 17 (2004) 177-184
27. Adkins B. T-cell function in newborn mice and humans. Immunol Today 20 (1999) 330-335
28. Arulanandam B.P., Van C.V., and Metzger D.W. IL-12 is a potent neonatal vaccine adjuvant. Eur J Immunol 29 (1999) 256-264
29. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 19 (2001) 3331-3346
30. Arulanandam B.P., Lynch J.M., Briles D.E., Hollingshead S., and Metzger D.W. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69 (2001) 6718-6724
31. McCool T.L., and Weiser J.N. Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Inf Imm 72 (2004) 5807-5813
32. Wu H.Y., Nahm M.H., Guo Y., Russell M.W., and Briles D.E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 175 (1997) 839-846
33. Giebink G.S., Koskela M., Vella P.P., Harris M., and Le C.T. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 167 (1993) 347-355
34. Giebink G.S., Meier J.D., Quartey M.K., Liebeler C.L., and Le C.T. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model. J Infect Dis 173 (1996) 119-127
35. White P., Hermansson A., Svanborg C., Briles D., and Prellner K. Effects of active immunization with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis media. ORL J Otorhinolaryngol Relat Spec 61 (1999) 206-211
36. AlonsoDeVelasco E., Dekker B.A., Verheul A.F., Feldman R.G., Verhoef J., and Snippe H. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. J Infect Dis 172 (1995) 562-565
37. Tuomanen E.I., Austrian R., and Masure H.R. Pathogenesis of pneumococcal infection. N Engl J Med 332 (1995) 1280-1284
38. Arulanandam B.P., O'Toole M., and Metzger D.W. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 180 (1999) 940-949
39. Arulanandam B.P., O'Toole M., and Metzger D.W. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 164 (2000) 3698-3704
40. Cohen J. IL-12 deaths: explanation and a puzzle. Science 270 (1995) 908
41. Kovarik J., Martinez X., Pihlgren M., Bozzotti P., Tao M.H., Kipps T.J., et al. Limitations of in vivo IL-12 supplementation strategies to induce Th1 early life responses to model viral and bacterial vaccine antigens. Virol 268 (2000) 122-131
42. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90 (1997) 2541-2548
43. Huber V.C., Arulanandam B.P., Arnaboldi P.M., Elmore M.K., Sheehan C.E., Kallakury B.V., et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol 3 (2003) 801-809